Phase 1 Lymphomas Clinical Trials
17 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–17 of 17 trials
Recruiting
Phase 1
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Kaposi SarcomaViral Associated MalignanciesEBV/KSHV-associated Lymphomas
National Cancer Institute (NCI)58 enrolled1 locationNCT04902443
Recruiting
Phase 1Phase 2
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
T-cell Lymphomas
Dizal Pharmaceuticals165 enrolled12 locationsNCT07496229
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited40 enrolled27 locationsNCT05984147
Recruiting
Phase 1
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
T-cell Prolymphocytic LeukemiaT-cell LymphomasNK-Cell Lymphomas+1 more
Memorial Sloan Kettering Cancer Center70 enrolled9 locationsNCT05010005
Recruiting
Phase 1Phase 2
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+8 more
Ossium Health, Inc.12 enrolled9 locationsNCT05589896
Recruiting
Phase 1
A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment
Precursor Cell Lymphoblastic Leukemia-LymphomaLymphomas Non-Hodgkin's B-Cell
Kite, A Gilead Company34 enrolled3 locationsNCT06539338
Recruiting
Phase 1
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited40 enrolled19 locationsNCT06755450
Recruiting
Phase 1Phase 2
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Locally AdvancedUnresectableMetastatic Cancers+1 more
Recursion Pharmaceuticals Inc.85 enrolled6 locationsNCT06678659
Recruiting
Phase 1
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
LymphomasB-cell Lymphomas
M.D. Anderson Cancer Center33 enrolled1 locationNCT05773040
Recruiting
Phase 1Phase 2
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkin LymphomaNon-Hodgkin's LymphomaLymphomas Non-Hodgkin's B-Cell+2 more
Estrella Biopharma, Inc.21 enrolled2 locationsNCT06343311
Recruiting
Phase 1
A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
Advanced Solid TumorsB-cell Non-Hodgkin Lymphomas
Antengene Biologics Limited80 enrolled4 locationsNCT06028373
Recruiting
Phase 1Phase 2
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb85 enrolled40 locationsNCT06035497
Recruiting
Phase 1
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Advanced Solid TumorRelapsed or Refractory Lymphomas
Lantern Pharma Inc.110 enrolled4 locationsNCT06132503
Recruiting
Phase 1Phase 2
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Relapsed Peripheral T-Cell LymphomasRefractory Peripheral T-Cell Lymphomas
Navy General Hospital, Beijing52 enrolled1 locationNCT06176027
Recruiting
Phase 1
L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma
Relapsed/Refractory B-cell Lymphomas
Henan Cancer Hospital22 enrolled1 locationNCT06478381
Recruiting
Phase 1
A First-in-Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients With Advanced Tumors
Solid Tumorsrelapsed/refractory Non-Hodgkin’s lymphomas (NHL)
Tigermed Australia Pty Ltd36 enrolled3 locationsACTRN12622001339741
Completed
Phase 1
A Phase I, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of single oral dose of HMPL-689 in Healthy Adult Participants
B-cell Non-Hodgkin Lymphomas
INC Research Australia Pty Ltd56 enrolled1 locationACTRN12616000451404